antiplatelet造句
1. Antiplatelet therapy is recommended for symptomatic patients.
2. Conclusion: The results suggest that GMS has antiplatelet function and reducing plasma fibrinogen effects.
3. EGB have definite antiplatelet aggregative activity, whether is it also through effecting the activity of platelet PDE to inhibit platelet aggregation?
4. Antiplatelet drugs, such as Plavix, are used to help prevent potentially dangerous blood clots from forming in people with heart disease.
5. Objective:To study the application value of neotype antiplatelet drug tirofiban in the interventional therapy of lower extremity deep venous thrombosis after acute thrombosis was formed.
6. So antiplatelet cure conduce to reduce the harmful events of cardia and cerebrovascular disorder.
7. If aspirin produces the expected antiplatelet effect, fibrinogen - coated beads will not light transmission will not increase.
8. Antiplatelet therapy is one of the important measures in secondary prevention of ischemic stroke.
9. In addition to their hypoglycaemic action it is probable that some or all of these compounds may have antiplatelet effects.
10. Improved thrombolytic therapy will most likely consist of potent specific plasminogen activators in combination with targeted anticoagulant and/or antiplatelet agents.
11. Conclusion: Atorvastatin, which is metabolited through the cytochrome P 450 ( CYP ) 3 A 4 Pathway, does not inhibits the antiplatelet activity ...
12. Stroke Prevention in Patients with Cervical Artery Dissection:Anticoagulant or Antiplatelet Therapy?
13. The search for a useful clinical laboratory diagnostic assay for the antiplatelet antibodies has been long and difficult.
14. Anticoagulation use has increased in nontargeted, low - risk groups in whom antiplatelet agents are appropriate.
15. For patients with cryptogenic stroke associated with mobile aortic arch thrombi, we suggest either oral anticoagulation or antiplatelet agents (Grade 2C).
17. International Circulation: Could you please talk about the choice of optimal strategy of early antiplatelet therapy in patients with ACS?
18. The report makes a number of practical recommendations to eliminate early discontinuation of antiplatelet therapy.
19. This case represents a potentially important complication of undiagnosed or conservatively managed iliopsoas impingement, particularly in patients taking anticoagulants or antiplatelet medications.
20. Bioactivity of RGD Tripeptides has been decreased. The results indicated there were antiplatelet aggregating effect of RGD on the time for dissolving of rabbit euglobulin of pla...
21. Staphylokinase variant K35R (DGR) is a bifunctional protein that possesses fibrinolytic and antiplatelet aggregation activities, and is a promising drug for thrombotic disorders.
22. The use of buflomedil should be considered in addition to an antiplatelet agent in patients with peripheral arterial obstructive disease and intermittent claudication.
23. Destruction occurs in immune-mediated thrombocytopenia, in which platelets become coated with antiplatelet antibodies and are removed from the circulation by the fixed phagocyte system.
24. Evidence based case report Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy?